Eurolens Research Faculty of Life Sciences The University of Manchester
Manchester, M60 1QD, United Kingdom
NCT Number: NCT01996787
The purpose of this study was to investigate the safety and efficacy of the Sauflon Clariti Monthly silicone hydrogel contact lenses with handling tint (Sauflon Pharmaceuticals Limited) by comparison with Air Optix Aqua silicone hydrogel lenses (Alcon Inc.)
Subjects used OptiFree Replenish solution (Alcon Lboratories Inc.) for daily lens maintenance, care and storage.
Looking for future studies?
Notify Me19 year–56 year
All sexes
Interventional
Not applicable
Manchester, M60 1QD, United Kingdom
I. Study characteristics:
The clinical study evaluates the clinical performance of a silicone hydrogel contact lens for daily wear, Clariti (including handling tint) (Sauflon Pharmaceuticals Ltd.) versus a predicate device, Air Optix Aqua (Alcon Inc.), in terms of lens performance, physiological response and subjective acceptance.
Subjects used OptiFRee Replenish solution (Alcon Laboratories Inc.) for daily lens maintenance, care and storage.
The key features were as follows:
II. Study period:
The study was conducted over one month of wear. Subjects were examined initially, and at two follow-up visits after two weeks and four weeks respectively. Study visits commenced on June 26, 2013 and completed on September 14, 2013.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Lenses will be worn on a daily wear basis (i.e. removed at night and stored in solution) and worn in the normal way. Lenses will be worn for one month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.
Lenses will be worn on a daily wear basis (i.e. removed at night and stored in solution) and worn in the normal way. Lenses will be worn for one month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.
Time frame: 1 month
Slit Lamp examination will be performed at the initial and follow-up visits. Slit lamp findings will be graded on a 0-4 scale (0=none;4=severe).
Time frame: 1 month
Adverse reactions will be recorded throughout the study. Adverse recations will be classified as serious, significant and non-significant.
Time frame: 1 month
Lens wear time is recorded for the two study lenses at follow-up visits.
Time frame: 1 month
LogMAR Visual Acuity at high contrast will be recorded before and after performeing an over-refraction at the initial, two-week and one-month visits.
Time frame: 1 month
Subjective scores for comfort, vision, handling and overall score will be recorded at the initial and follow-up visits. The subjective scores will be graded on a 0-5 scale.
Time frame: 1 month
The presence or absence of symptoms, problems and complaints will be recorded at two-weeks and one-month visits.
Time frame: 1 month
All subjects discontinuations will be recorded at the two-week and one-month visits.
Time frame: 1 month
Refraction was undertaken and recorded for all subjects at the initial, two-weeks and one-month visits.
Time frame: 1 month
Keratometry measures will be performed at the initial and one-month visits for all subjects.
Sauflon Pharmaceuticals Ltd
Industry
The Clinical Performance of the Clariti Contact Lens (Including Handling Tint) for Daily Wear
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06758076
Eye Diseases, Hyperopia
Manchester, United Kingdom
View Trial DetailsNCT06869044
Eye Diseases, Hyperopia
Berkeley, California, United States
View Trial DetailsNCT07276347
Eye Diseases, Hyperopia
Bloomington, Indiana, United States
View Trial DetailsNCT06873048
Astigmatism, Eye Diseases
Waterloo, Ontario, Canada
View Trial Details